Delafloxacin
A fluoroquinolone antibiotic with a unique anionic character that provides enhanced activity against Gram-positive bacteria including MRSA in addition to Gram-negative organisms, used for acute bacterial skin infections and community-acquired pneumonia. Its negative charge at physiological pH improves penetration into the acidic environment of infection sites.
Masse moléculaire
440,8000 g/mol
LogP
2,70
TPSA
120,00 Ų
Règle des 5 de Lipinski
Conforme
Mécanisme d'action
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Structure 2D
Cite this structure
Embed this structure
SMILES
Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(O)C4)c(Cl)c32)c(F)cc1F
InChI
InChI=1S/C18H12ClF3N4O4/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30)
Molecular Formula
C18H12ClF3N4O4
HBD / HBA
3 / 11
Liaisons Rotatives
3
Atomes Lourds
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A fluoroquinolone antibiotic with a unique anionic character that provides enhanced activity against Gram-positive bacteria including MRSA in addition to Gram-negative organisms, used for acute bacterial skin infections and community-acquired pneumonia. Its negative charge at physiological pH improves penetration into the acidic environment of infection sites.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Yes, Delafloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105637. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 487101. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="delafloxacin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/delafloxacin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/delafloxacin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/delafloxacin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="delafloxacin"></drugfyi-drug>